Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.

Nakachi I, Helfrich BA, Spillman MA, Mickler EA, Olson CJ, Rice JL, Coldren CD, Heasley LE, Geraci MW, Stearman RS.

Clin Transl Sci. 2016 Dec;9(6):293-301. doi: 10.1111/cts.12413. Epub 2016 Oct 20.


AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.


Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA Jr.

Mol Cancer Ther. 2016 Oct;15(10):2314-2322. Epub 2016 Aug 5.


FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.


A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.


Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J.

Cancer Res. 2012 Aug 15;72(16):4154-64. doi: 10.1158/0008-5472.CAN-11-2848. Epub 2012 Jun 27.


Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.


ZEB1-responsive genes in non-small cell lung cancer.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA.

Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.


Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE.

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.


EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA.

Ann Oncol. 2008 Jun;19(6):1053-9. doi: 10.1093/annonc/mdn006. Epub 2008 Feb 27.


Combining halogen bonds and hydrogen bonds in the modular assembly of heteromeric infinite 1-D chains.

Aakeröy CB, Desper J, Helfrich BA, Metrangolo P, Pilati T, Resnati G, Stevenazzi A.

Chem Commun (Camb). 2007 Nov 7;(41):4236-8.


Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.

Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D.

Mol Cancer Ther. 2007 Jun;6(6):1683-91. Epub 2007 May 31.


Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.


Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr.

Mol Cancer Res. 2006 Aug;4(8):521-8.


A high-yielding supramolecular reaction.

Aakeröy CB, Beatty AM, Helfrich BA.

J Am Chem Soc. 2002 Dec 4;124(48):14425-32.


Solution and solid-state models of peptide CH...O hydrogen bonds.

Baures PW, Beatty AM, Dhanasekaran M, Helfrich BA, Pérez-Segarra W, Desper J.

J Am Chem Soc. 2002 Sep 25;124(38):11315-23.


Syntheses and bioactivities of substituted 9,10-dihydro-9,10-[1,2]benzenoanthracene-1,4,5,8-tetrones. Unusual reactivities with amines.

Hua DH, Tamura M, Huang X, Stephany HA, Helfrich BA, Perchellet EM, Sperfslage BJ, Perchellet JP, Jiang S, Kyle DE, Chiang PK.

J Org Chem. 2002 May 3;67(9):2907-12.


Epidermal growth factor receptor family in lung cancer and premalignancy.

Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr.

Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14. Review.


Effects of recombinant neutral endopeptidase (EC on the growth of lung cancer cell lines in vitro and in vivo.

Bunn PA Jr, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE.

Clin Cancer Res. 1998 Nov;4(11):2849-58.


Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.

McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.

Cancer Res. 1992 Nov 15;52(22):6318-22.


Radiant heat-induced hyperthermia in mice: in vivo effects on the immune system.

Greeley EH, Helfrich BA, Feuerman LL, Cain CA, Segre M.

Int J Hyperthermia. 1992 Mar-Apr;8(2):209-20.


Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI.

J Immunol. 1989 Dec 15;143(12):4282-6.


Age-related changes in the degeneracy of the mouse T-cell repertoire.

Helfrich BA, Segre M, Segre D.

Cell Immunol. 1989 Jan;118(1):1-9.


Supplemental Content

Loading ...
Support Center